# Colaboracion Evita: HPV-Related Cancer Prevention Partnership Center

> **NIH NIH U54** · FRED HUTCHINSON CANCER CENTER · 2024 · $1,552,556

## Abstract

PROJECT SUMMARY – OVERALL
Worldwide, cervical cancer is the fourth leading cause of cancer incidence and mortality; 80% of cervical
cancers arise and 87% of cervical cancer deaths occur in low and lower-middle income countries. In Peru,
cervical cancer is diagnosed at a rate of 17 per 100,000 women per year, and in the DR at 23 per 100,000
annually among women in the general population. The burden of cervical cancer is substantially increased
among women living with HIV (WLWH), although the exact rates are not well described. Although HPV
vaccines are safe and effective as primary prevention, they have limited availability in low resource settings
and the optimal regimen of vaccine doses for HIV-infected persons in such settings has not been defined.
Furthermore, delivery of cervical cancer prevention and treatment of precursors for WLWH in low- and middle-
income countries is impeded by approaches that are often costly, require multiple visits and extensive provider
training. Moreover, many of these are not suitable for delivery within an HIV primary care model.
The Cervical Cancer Prevention Partnership (C2P2) Center involves two clinical trial sites, in Peru and the
Dominican Republic, and three cores (Administrative and Coordinating Core, Statistics and Data Management
Core and Central Laboratory Core) in Seattle. Investigators in the C2P2 Center will jointly design, conduct and
analyze three clinical trials with the goal of moving toward elimination of cervical cancer among highly
vulnerable populations with HIV in low resource settings in Latin America and the Caribbean (LAC). We seek
to improve the quality and efficiency of prevention strategies using new approaches that will augment the
existing infrastructure at local HIV clinics in Peru and the Dominican Republic (DR). The aims of the
proposed Clinical Trials Center span the continuum of cervical cancer prevention from vaccination
through treatment. The trials we propose will address these technical issues and provide a more direct pipeline
for prevention. In this C2P2 Center, our overarching aims are:
  Specific Aim 1: To test the effectiveness of novel approaches to cervical cancer prevention in high-
 burden HIV-infected populations in Peru and the DR by performing three clinical trials. One will assess
 the ability of HPV vaccination regimens to elicit long-lasting B cell responses, and two will assess novel
 screening, triage, and treatment approaches that will improve the quality and reach of prevention in
 low-resource settings throughout the LAC region.
  Specific Aim 2: To build a robust multidirectional collaboration between study investigators at all sites
 that serves the needs of providers who care for women living with HIV. The Center will engage with
 leaders in the region to enhance the sustainability of efforts that target future elimination of cervical
 cancer through multiple high-impact prevention and treatment strategies.

## Key facts

- **NIH application ID:** 10915693
- **Project number:** 5U54CA242977-07
- **Recipient organization:** FRED HUTCHINSON CANCER CENTER
- **Principal Investigator:** Robinson Cabello
- **Activity code:** U54 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $1,552,556
- **Award type:** 5
- **Project period:** 2019-09-18 → 2026-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10915693

## Citation

> US National Institutes of Health, RePORTER application 10915693, Colaboracion Evita: HPV-Related Cancer Prevention Partnership Center (5U54CA242977-07). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10915693. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*